The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Mechanism-Based Target Identification and Drug Discovery in Cancer Research
Abstract
Cancer as a disease in the human population is becoming a larger health problem, and the medicines used as treatments have clear limitations. In the past 20 years, there has been a tremendous increase in our knowledge of the molecular mechanisms and pathophysiology of human cancer. Many of these mechanisms have been exploited as new targets for drug development in the hope that they will have greater antitumor activity with less toxicity to the patient than is seen with currently used medicines. The fruition of these efforts in the clinic is just now being realized with a few encouraging results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483
Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen
Mayer, T. U., Kapoor, T. M., Haggarty, S. J., King, R. W., Schreiber, S. L., & Mitchison, T. J. (1999) · Science · doi:10.1126/science.286.5441.971 · Cited by 1,727
Molecular themes in oncogenesis
Bishop, J. M. (1991) · Cell · doi:10.1016/0092-8674(91)90636-d · Cited by 1,637
Inhibition of telomerase limits the growth of human cancer cells
Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H. M., Meyerson, M., & Weinberg, R. A. (1999) · Nature Medicine · doi:10.1038/13495 · Cited by 1,030
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996
Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W., & Friend, S. H. (1997) · Science · doi:10.1126/science.278.5340.1064 · Cited by 773
Holash, J., Wiegand, S. J., & Yancopoulos, G. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203035 · Cited by 744
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Eliceiri, B. P., & Cheresh, D. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6869 · Cited by 649
Drug target validation and identification of secondary drug target effects using DNA microarrays
Marton, M. J., DeRisi, J. L., Bennett, H. A., Iyer, V. R., Meyer, M. R., Roberts, C. J., Stoughton, R., Burchard, J., Slade, D., Dai, H., et al. (1998) · Nature Medicine · doi:10.1038/3282 · Cited by 643
Herbert, B.-S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., & Corey, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14276 · Cited by 539
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Goldenberg, M. M. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88288-0 · Cited by 453
Fambrough, D., McClure, K., Kazlauskas, A., & Lander, E. S. (1999) · Cell · doi:10.1016/s0092-8674(00)80785-0 · Cited by 439
The Molecular Pharmacology of SERMs
McDonnell, D. P. (1999) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(99)00177-0 · Cited by 299
A common pharmacophore for cytotoxic natural products that stabilize microtubules
Ojima, I., Chakravarty, S., Inoue, T., Lin, S., He, L., Horwitz, S. B., Kuduk, S. D., & Danishefsky, S. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4256 · Cited by 250
Coupling cell division and cell death to microtubule dynamics
Sorger, P. K., Dobles, M., Tournebize, R., & Hyman, A. A. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80081-6 · Cited by 222
Apoptosis and cancer drug targeting
Sellers, W. R., & Fisher, D. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9053 · Cited by 216
p53-independent apoptosis induced by paclitaxel through an indirect mechanism
Lanni, J. S., Lowe, S. W., Licitra, E. J., Liu, J. O., & Jacks, T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9679 · Cited by 172
Selective oestrogen receptor modulation
Levenson, A. S., & Jordan, V. C. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00297-x · Cited by 156
Anticancer drug targets: approaching angiogenesis
Keshet, E., & Ben‐Sasson, S. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8849 · Cited by 135
Matrix metalloproteinase inhibitors 1998
Beckett, R. P., & Whittaker, M. A. (1998) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.8.3.259 · Cited by 133
Pharmaceutical research in molecular oncology
Gibbs, J. (1994) · Cell · doi:10.1016/0092-8674(94)90189-9 · Cited by 132
Self-citationSrc homology-2 domains: Structure, mechanisms, and drug discovery
Sawyer, T. K. (1998) · Biopolymers · Cited by 126
Selective oestrogen receptor modulation
Levenson, A. S., & Jordan, V. C. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00183-5 · Cited by 124
For Better or Worse? Telomerase Inhibition and Cancer
de Lange, T., & Jacks, T. (1999) · Cell · doi:10.1016/s0092-8674(00)81955-8 · Cited by 119
Therapeutic application of anti-growth factor receptor antibodies
Fan, Z., & Mendelsohn, J. M. (1998) · Current Opinion in Oncology · doi:10.1097/00001622-199801000-00011 · Cited by 119
Gescher, A. J. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(98)00069-x · Cited by 103
Farnesyltransferase inhibitors: targeting the molecular basis of cancer
Oliff, A. I. (1999) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00007-4 · Cited by 97
Choosing anticancer drug targets in the postgenomic era
Kaelin, W. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8888 · Cited by 79
Small molecule inhibitors of receptor tyrosine kinases
Boschelli, D. H. (1999) · Drugs of the Future · doi:10.1358/dof.1999.024.05.858622 · Cited by 70
Hamby, J. M., & Showalter, H. D. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00053-9 · Cited by 66
Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund, J. T., Monia, B. P., Kwoh, T. J., & Dorr, F. A. (1999) · PubMed · Cited by 41
Cited by
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
“Because tyrosine kinases are among the most frequently activated oncogenic proteins in cancer cell”
BackgroundThun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
The Hedgehog and Wnt signalling pathways in cancer
Taipale, J., & Beachy, P. A. (2001) · Nature · doi:10.1038/35077219 · Cited by 1,393
Metadata
- Authors
- Gibbs, J. B.
- Venue
- Science
- Published
- 2000-03-17
- Volume
- 287
- Issue
- 5460
- Pages
- 1969-1973
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2000196730
- Cited by
- 606
- References
- 41
- FWCI
- 29.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.